Yuhan Corp
KRX:000100

Watchlist Manager
Yuhan Corp Logo
Yuhan Corp
KRX:000100
Watchlist
Price: 104 300 KRW -1.04% Market Closed
Market Cap: 8.5T KRW

Net Margin
Yuhan Corp

3.1%
Current
5%
Average
5.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3.1%
=
Net Income
65.8B
/
Revenue
2.1T

Net Margin Across Competitors

Country Company Market Cap Net
Margin
KR
Yuhan Corp
KRX:000100
7.7T KRW
3%
US
Eli Lilly and Co
NYSE:LLY
699.1B USD
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
373.4B USD
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK
35%
CH
Roche Holding AG
SIX:ROG
211.2B CHF
14%
CH
Novartis AG
SIX:NOVN
184.2B CHF
24%
UK
AstraZeneca PLC
LSE:AZN
166.2B GBP
14%
US
Merck & Co Inc
NYSE:MRK
193.3B USD
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
133.5B USD
13%

Yuhan Corp
Glance View

Market Cap
7.7T KRW
Industry
Pharmaceuticals

In the bustling landscape of South Korea's pharmaceutical industry, Yuhan Corp. stands out as a venerable institution with a rich legacy and a forward-thinking approach. Founded in 1926, Yuhan has carved out a respected space in the market through its commitment to developing, manufacturing, and distributing a wide array of pharmaceutical and healthcare products. The company operates across multiple segments, focusing on prescription drugs, over-the-counter medications, and consumer health products that cater to various needs from chronic diseases to everyday health care. Yuhan’s product portfolio includes a combination of in-house innovations and collaborations with global leaders, which has allowed it to build a sustainable revenue stream and secure a substantial market share both domestically and internationally. At the core of Yuhan's business model is the strategic integration of research and development with commercial prowess. The company invests significantly in R&D to stay ahead of industry trends and meet evolving patient needs. This focus on innovation is complemented by strategic partnerships and licensing agreements with international pharmaceutical corporations, allowing Yuhan to introduce groundbreaking therapies to the Korean market. Additionally, Yuhan capitalizes on its robust distribution network, ensuring wide accessibility and penetration of its products. These efforts not only reinforce Yuhan’s position as a leader in the pharmaceutical sector but also fuel its steady financial growth, providing a reliable return on investment through a combination of direct sales and strategic partnerships.

Intrinsic Value
65 875.92 KRW
Overvaluation 37%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3.1%
=
Net Income
65.8B
/
Revenue
2.1T
What is the Net Margin of Yuhan Corp?

Based on Yuhan Corp's most recent financial statements, the company has Net Margin of 3.1%.

Back to Top